Treatment with Endeavor Biomedicines’ experimental oral therapy ENV-101 (taladegib) improved lung function in people with IPF ...

A Phase 2 trial testing experimental therapy CAL101 in people with IPF is recruiting participants. CAL101 has been granted ...

This Veterans Day, columnist Samuel Kirton writes about the PACT Act, which expanded coverage for veterans exposed to toxic substances.

Columnist Samuel Kirton has nothing but praise for caregivers, who represent the best of what is right in the world.

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

Hyperbaric oxygen therapy can counteract some of the key features of pulmonary fibrosis (PF) in mice and human lung cells, a recent study reveals. The findings suggest this treatment, involving the ...

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...